Characteristics and survival of patients with advanced cancer and p53 mutations

Rabih Said, Yang Ye, David S. Hong, Filip Janku, Siqing Fu, Aung Naing, Jennifer J. Wheler, Razelle Kurzrock, Christoforos Thomas, Gary A. Palmer, Kenneth R. Hess, Kenneth Aldape, Apostolia M. Tsimberidou

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

P53 mutations are associated with invasive tumors in mouse models. We assessed the p53 mutations and survival in patients with advanced cancer treated in the Phase I Program. Of 691 tested patients, 273 (39.5%) had p53 mutations. Patients with p53 mutations were older (p<.0001) and had higher numbers of liver metastases (p=.005). P53 mutations were associated with higher numbers of other aberrations; PTEN (p=.0005) and HER2 (p=.003) aberrations were more common in the p53 mutation group. No survival difference was observed between patients with p53 mutations and those with wild-type p53. In patients with wild-type p53 and other aberrations, patients treated with matched-therapy against the additional aberrations had longer survival compared to those treated with non-matched-therapy or those who received no therapy (median survival, 26.0 vs. 11.8 vs. 9.8 months, respectively; p=.0007). Results were confirmed in a multivariate analysis (p=.0002). In the p53 mutation group with additional aberrations, those who received matched-therapy against the additional aberrations had survival similar to those treated with non-matched-therapy or those who received no therapy (p=.15). In conclusion, our results demonstrated resistance to matched-targeted therapy to the other aberrations in patients with p53 mutations and emphasize the need to overcome this resistance.

Original languageEnglish (US)
Pages (from-to)3871-3879
Number of pages9
JournalOncotarget
Volume5
Issue number11
DOIs
StatePublished - 2014

Keywords

  • Matched therapy
  • Molecular aberrations
  • P53 mutations

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Characteristics and survival of patients with advanced cancer and p53 mutations'. Together they form a unique fingerprint.

Cite this